QDEL

QuidelOrtho Corporation (QDEL) | Rumor.io

QuidelOrtho

QDEL

Attention (50-day avg)0%

Attention rank (50-day avg)#3,744

Bullish sentiment (50-day avg)60%

Price to earnings ratio-0.65

Market capitalization742.7M

Earnings per share-15.3

Dividend yield (TTM)—

Revenue (annual)2.7B

Net income (annual)-1.1B

Social

What share of all stock conversation is about QDEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 7

QuidelOrtho Corporation's ($QDEL) stock price fell by -24.88% due to lowered revenue and earnings expectations, despite beating Wall Street's expectations in Q2 with $630.9M in revenue and $0.13 EPS.
The company's stock price declined by ~23.7% following broader healthcare sector volatility and profit-taking, with the share price falling to $12.45.
QuidelOrtho's Q2 report was met with disappointment, as the company significantly lowered its outlook for the full year, with the stock price at 1X-2X adjusted EBITDA representing extreme value.

Generated by AI

Sentiment

Of the messages about QDEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	63.12% -11.55
Bearish	—	—	—	36.88% +11.55

Bullish· Feb 14

QDEL is a strong buy opportunity given its 98% ownership and trading at 1X revenue.
The company has a history of beating its own guidance and analyst expectations, despite its stock price moving slightly.
QDEL is poised for a rebound, with analysts setting new price targets above $76 and the company guiding for FY24 adj. EPS of $2.40-$3.07.

Bearish· Feb 14

The company has a poor management team, as evidenced by the dilutive deal to acquire Ortho on Thanksgiving Friday, which led to a stock price decline that never recovered.
The company has struggled with sales and cost synergies, failing to materialize after the acquisition, and has experienced a significant decline in revenue, with Q4 adj. EPS of $1.17 falling short of analysts' expectations of $2.04.
The company's guidance has been missed, with a recent forecast of $3 for 2024, significantly lower than the expected $4.75, and analysts have downgraded the stock, with JPMorgan Chase cutting its price target to $37 from $66.

Generated by AI

Topics

Of the messages about QDEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	76.06%
Technical Analysis	100%	100%	100%	8.51%
Analysts	0%	0%	0%	4.26%
Earnings	0%	0%	0%	8.51%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	2.66%

Earnings· Feb 18

QuidelOrtho Corporation (QDEL) reported Q4 EPS of $11.07, beating the estimate of $10.14.
The company's revenue of $809.20M also beat the estimate of $808.35M.
QDEL's earnings beat was significant, with a $0.97 per share beat, but revenue only met expectations.

Analysts· Jul 18

QuidelOrtho Corporation ($QDEL) was upgraded to "Buy" by Zacks Investment Research and Canaccord Genuity, with target prices ranging from $30 to $42.
William Blair upgraded Quidel Corporation to Outperform, with one report ranking them 45th in their rankings.
The upgrades were based on Quidel's performance and potential for growth, with analysts citing the company's strengths in the market.

Announcements· Jan 6

Quidel Corporation (QDEL) expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million.
Quidel's COVID-19 revenues in the fourth quarter of 2021 are expected to be approximately $510 million, with the company stating that the fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel.
Quidel will present virtually at the 40th Annual J.P. Morgan Healthcare Conference, with the conference details and presentation date not specified in the provided information.

Technical Analysis· Aug 27

$QDEL's price has moved significantly, slicing through its 50-day SMA with volume, and is currently oversold with an RSI of 22-23.
The stock has experienced a huge down gap and is trading below its bottom BB, with an RSI at 10-12, indicating extreme oversold conditions.
$QDEL is showing signs of weakness, with its price unable to recover above its 200-day EMA since August 21, and is now approaching its 50% fib and 200SMA levels.

Generated by AI

Community

Of the messages about QDEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80%	83.33%	40.34%
Newcomers	100%	20%	16.67%	59.66%

Regulars· Feb 15

QuidelOrtho Corporation's stock traded at 1912% above average volume, with a closing price decrease of -32.20%.
The company's put volume was unusually high, at 1.5K, representing 524% of the 30-day average put volume of 277.25.
The stock also experienced an unusually high call volume of 4.9K, which is 1.9K% of the 30-day average call volume of 263.3.

Newcomers· Jun 29

QuidelOrtho Corporation is in talks to sell its point-of-care testing unit, according to Financial Times, which may be behind the recent stock price increase.
The stock has experienced a significant price increase, with a +36% move on strong volume, breaking out from an accumulation zone and showing clear momentum re-acceleration.
Private equity firms, including Advent International and SK Capital Partners, are reportedly interested in buying QuidelOrtho's point-of-care testing unit, which may be a major factor in the stock's recent price increase.

Generated by AI

--QuidelOrtho Corporation, a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room. Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates. Hosted by Josh Casey, this episode...

5d agoNasdaq

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

6d agotheglobeandmail.com

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

14d agoYahoo Finance

Faster Answers, Better Decisions: ADLM 2026 Highlights – Company Announcement

1mo agoFinancial Times

Faster Answers, Better Decisions: ADLM 2026 Highlights

QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

1mo agoYahoo Finance Australia

QuidelOrtho (QDEL) Is Up 6.0% After Cutting 2026 Revenue Outlook Amid Narrowing Losses – What's Changed

In early August 2026, QuidelOrtho reported second-quarter 2026 results showing sales of US$630.9 million and a net loss of US$92.9 million, alongside narrower losses per share than a year earlier. However, for the first half of 2026, sales eased to US$1.25 billion and the company reduced its full-year revenue outlook to US$2.52–2.60 billion, highlighting softer expectations despite improving losses. With QuidelOrtho lowering its full-year 2026 revenue guidance, we’ll now examine how this...

1mo agoYahoo Finance

Also Discussed

Investors talking about QDEL also mention

#	Name	Attention
1	Fulgent Genetics, Inc.FLGT	0%0
2	Qiagen N.V.QGEN	0%+0
3	Becton, Dickinson and CompanyBDX	0%0
4	OraSure Technologies Inc.OSUR	0%new
5	HOLX - Hologic, Inc.	——
6	Labcorp Holdings Inc.LH	0%0
7	Danaher Corp.DHR	0.02%+0.02
8	Meridian Bioscience IncVIVO	0%0
9	FLDM - Standard BioTools Inc.	——
10	PKI - PerkinElmer, Inc.	——

QuidelOrtho Corporation

Healthcare
Medical Devices

QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine. Its offerings are designed to support disease detection, monitoring, and clinical decision-making in settings ranging from hospitals and reference laboratories to blood banks and other care environments. QuidelOrtho serves a global market and plays an important role in providing tools that help clinicians identify infections, manage chronic conditions, and support transfusion safety. Headquartered in San Diego, California, QuidelOrtho Corporation combines broad diagnostic expertise with a diversified portfolio that addresses both routine and specialized testing needs in modern healthcare.

Website

Location

9975 Summers Ridge Road

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about QDEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 7

QuidelOrtho Corporation's ($QDEL) stock price fell by -24.88% due to lowered revenue and earnings expectations, despite beating Wall Street's expectations in Q2 with $630.9M in revenue and $0.13 EPS.
The company's stock price declined by ~23.7% following broader healthcare sector volatility and profit-taking, with the share price falling to $12.45.
QuidelOrtho's Q2 report was met with disappointment, as the company significantly lowered its outlook for the full year, with the stock price at 1X-2X adjusted EBITDA representing extreme value.

Generated by AI

Sentiment

Of the messages about QDEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	63.12% -11.55
Bearish	—	—	—	36.88% +11.55

Bullish· Feb 14

QDEL is a strong buy opportunity given its 98% ownership and trading at 1X revenue.
The company has a history of beating its own guidance and analyst expectations, despite its stock price moving slightly.
QDEL is poised for a rebound, with analysts setting new price targets above $76 and the company guiding for FY24 adj. EPS of $2.40-$3.07.

Bearish· Feb 14

The company has a poor management team, as evidenced by the dilutive deal to acquire Ortho on Thanksgiving Friday, which led to a stock price decline that never recovered.
The company has struggled with sales and cost synergies, failing to materialize after the acquisition, and has experienced a significant decline in revenue, with Q4 adj. EPS of $1.17 falling short of analysts' expectations of $2.04.
The company's guidance has been missed, with a recent forecast of $3 for 2024, significantly lower than the expected $4.75, and analysts have downgraded the stock, with JPMorgan Chase cutting its price target to $37 from $66.

Generated by AI

Topics

Of the messages about QDEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	76.06%
Technical Analysis	100%	100%	100%	8.51%
Analysts	0%	0%	0%	4.26%
Earnings	0%	0%	0%	8.51%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	2.66%

Earnings· Feb 18

QuidelOrtho Corporation (QDEL) reported Q4 EPS of $11.07, beating the estimate of $10.14.
The company's revenue of $809.20M also beat the estimate of $808.35M.
QDEL's earnings beat was significant, with a $0.97 per share beat, but revenue only met expectations.

Analysts· Jul 18

QuidelOrtho Corporation ($QDEL) was upgraded to "Buy" by Zacks Investment Research and Canaccord Genuity, with target prices ranging from $30 to $42.
William Blair upgraded Quidel Corporation to Outperform, with one report ranking them 45th in their rankings.
The upgrades were based on Quidel's performance and potential for growth, with analysts citing the company's strengths in the market.

Announcements· Jan 6

Quidel Corporation (QDEL) expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million.
Quidel's COVID-19 revenues in the fourth quarter of 2021 are expected to be approximately $510 million, with the company stating that the fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel.
Quidel will present virtually at the 40th Annual J.P. Morgan Healthcare Conference, with the conference details and presentation date not specified in the provided information.

Technical Analysis· Aug 27

$QDEL's price has moved significantly, slicing through its 50-day SMA with volume, and is currently oversold with an RSI of 22-23.
The stock has experienced a huge down gap and is trading below its bottom BB, with an RSI at 10-12, indicating extreme oversold conditions.
$QDEL is showing signs of weakness, with its price unable to recover above its 200-day EMA since August 21, and is now approaching its 50% fib and 200SMA levels.

Generated by AI

Community

Of the messages about QDEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80%	83.33%	40.34%
Newcomers	100%	20%	16.67%	59.66%

Regulars· Feb 15

QuidelOrtho Corporation's stock traded at 1912% above average volume, with a closing price decrease of -32.20%.
The company's put volume was unusually high, at 1.5K, representing 524% of the 30-day average put volume of 277.25.
The stock also experienced an unusually high call volume of 4.9K, which is 1.9K% of the 30-day average call volume of 263.3.

Newcomers· Jun 29

QuidelOrtho Corporation is in talks to sell its point-of-care testing unit, according to Financial Times, which may be behind the recent stock price increase.
The stock has experienced a significant price increase, with a +36% move on strong volume, breaking out from an accumulation zone and showing clear momentum re-acceleration.
Private equity firms, including Advent International and SK Capital Partners, are reportedly interested in buying QuidelOrtho's point-of-care testing unit, which may be a major factor in the stock's recent price increase.

Generated by AI

QuidelOrtho

Social

Aug 7

Bullish· Feb 14

Bearish· Feb 14

Earnings· Feb 18

Analysts· Jul 18

Announcements· Jan 6

Technical Analysis· Aug 27

Regulars· Feb 15

Newcomers· Jun 29

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

Faster Answers, Better Decisions: ADLM 2026 Highlights – Company Announcement

Faster Answers, Better Decisions: ADLM 2026 Highlights

QuidelOrtho (QDEL) Is Up 6.0% After Cutting 2026 Revenue Outlook Amid Narrowing Losses – What's Changed

Also Discussed

QuidelOrtho Corporation

Company Information

Location

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

Faster Answers, Better Decisions: ADLM 2026 Highlights – Company Announcement

Faster Answers, Better Decisions: ADLM 2026 Highlights

QuidelOrtho (QDEL) Is Up 6.0% After Cutting 2026 Revenue Outlook Amid Narrowing Losses – What's Changed

Also Discussed

Social

Aug 7

Bullish· Feb 14

Bearish· Feb 14

Earnings· Feb 18

Analysts· Jul 18

Announcements· Jan 6

Technical Analysis· Aug 27

Regulars· Feb 15

Newcomers· Jun 29